Cyclosporine Effects on Optic Nerve and Retinal Vasculitis in Behçet's Disease

Overview

Journal Doc Ophthalmol

Specialty Ophthalmology

Date 1992 Jan 1

PMID 1425128

Citations 5

Authors

P S Chavis

S R Antonios

K F Tabbara

Affiliations

Soon will be listed here.

Abstract

In a prospective, open clinical trial, we studied long-term effects of cyclosporine (CsA) on the optic nerve and retinal vasculitis in 14 Behçet's disease patients. Patients were treated with CsA and corticosteroids for a mean period of 42 months, with a range of 36 to 52 months. They received an initial CsA dosage of 7 mg/kg/day for three days, followed by 5 mg/kg/day, and prednisone 1 mg/kg/day for three to five days, tapered to 0.4 mg/kg/day. CsA was tapered when clinical response was noted. Improvement occurred in visual acuity and visual field defects secondary to papillitis, optic neuritis, macular neuroretinitis, and retinal phlebitis, but not with retinal arteritis. Despite a 12/14 (85%) exacerbation rate, no permanent liver or renal lab tests abnormalities were noted. Intermittent, low-dose CsA therapy may be considered in treatment of acute retinal and optic nerve vasculitis assisted with Behçet's disease.

Citing Articles

Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults.

Edwards Mayhew R, Li T, McCann P, Leslie L, Strong Caldwell A, Palestine A Cochrane Database Syst Rev. 2022; 10:CD014831.

PMID: 36315029 PMC: 9621106. DOI: 10.1002/14651858.CD014831.pub2.

Update on the therapy of Behçet disease.

Saleh Z, Arayssi T Ther Adv Chronic Dis. 2014; 5(3):112-34.

PMID: 24790727 PMC: 3992825. DOI: 10.1177/2040622314523062.

Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.

Cakar Ozdal P, Ortac S, Taskintuna I, Firat E Doc Ophthalmol. 2003; 105(3):301-12.

PMID: 12539855 DOI: 10.1023/a:1021227019915.

Pharmacotherapy for Behcet's syndrome.

Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P Cochrane Database Syst Rev. 2000; (2):CD001084.

PMID: 10796413 PMC: 7032645. DOI: 10.1002/14651858.CD001084.

Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Faulds D, Goa K, Benfield P Drugs. 1993; 45(6):953-1040.

PMID: 7691501 DOI: 10.2165/00003495-199345060-00007.

References

Tabbara K . Chlorambucil in Behçet's disease. A reappraisal. Ophthalmology. 1983; 90(8):906-8. DOI: 10.1016/s0161-6420(83)80014-1. View

Cotticelli L, Federico A, Cotrufo R, Annunziata P, Di Iorio G . Behçet's disease: an unusual case with bilateral obliterating retinal panarteritis and ischemic optic atrophy. Ophthalmologica. 1980; 180(6):328-32. DOI: 10.1159/000308995. View

ODuffy J, Robertson D, GOLDSTEIN N . Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med. 1984; 76(1):75-84. DOI: 10.1016/0002-9343(84)90753-8. View

Benezra D, Cohen E . Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol. 1986; 70(8):589-92. PMC: 1040777. DOI: 10.1136/bjo.70.8.589. View

Chamberlain M . Behcet's syndrome in 32 patients in Yorkshire. Ann Rheum Dis. 1977; 36(6):491-99. PMC: 1000153. DOI: 10.1136/ard.36.6.491. View

Colvard D, Robertson D, ODuffy J . The ocular manifestations of Behçet's disease. Arch Ophthalmol. 1977; 95(10):1813-7. DOI: 10.1001/archopht.1977.04450100115015. View

Mochizuki M, Nussenblatt R, Kuwabara T, Gery I . Effects of cyclosporine and other immunosuppressive drugs on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci. 1985; 26(2):226-32. View

Diaz-Llopis M, Cervera M, Menezo J . Cyclosporin A treatment of Behçet's disease: a long-term study. Curr Eye Res. 1990; 9 Suppl:17-23. DOI: 10.3109/02713689008999414. View

Aoki K, Sugiura S . Immunosuppressive treatment of Behcet's disease. Mod Probl Ophthalmol. 1976; 16:309-13. View

10.

Chung Y, Liu J, Tsi S . Behçet's disease in Taiwan--a review of 53 cases. Jpn J Ophthalmol. 1986; 30(3):318-23. View

11.

BUCKLEY 3rd C, GILLS Jr J . Cyclophosphamide therapy of Behcet's disease. J Allergy. 1969; 43(5):273-83. DOI: 10.1016/0021-8707(69)90148-8. View

12.

Binder A, Graham E, Sanders M, Dinning W, James D, DENMAN A . Cyclosporin A in the treatment of severe Behçet's uveitis. Br J Rheumatol. 1987; 26(4):285-91. DOI: 10.1093/rheumatology/26.4.285. View

13.

Nussenblatt R, Dinning W, Fujikawa L, Chan C, Palestine A . Local cyclosporine therapy for experimental autoimmune uveitis in rats. Arch Ophthalmol. 1985; 103(10):1559-62. DOI: 10.1001/archopht.1985.01050100135035. View

14.

Nussenblatt R, Palestine A, Chan C . Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983; 96(3):275-82. DOI: 10.1016/s0002-9394(14)77814-6. View

15.

de Vries J, Baarsma G, Zaal M, Rothova A, Buitenhuis H, Schweitzer C . Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol. 1990; 74(6):344-9. PMC: 1042124. DOI: 10.1136/bjo.74.6.344. View

16.

Wolf R, Fudenberg H, Welch T, Spitler L, ZIFF M . Treatment of Bechçet's syndrome with transfer factor. JAMA. 1977; 238(8):869-71. View

17.

MAMO J . The rate of visual loss in Behçet's disease. Arch Ophthalmol. 1970; 84(4):451-2. DOI: 10.1001/archopht.1970.00990040453009. View

18.

Nussenblatt R, Palestine A, Chan C, Roberge F . Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985; 92(4):467-71. DOI: 10.1016/s0161-6420(85)34001-0. View

19.

Muftuoglu A, Pazarli H, Yurdakul S, Yazici H, Ulku B, Tuzun Y . Short term cyclosporin A treatment of Behçet's disease. Br J Ophthalmol. 1987; 71(5):387-90. PMC: 1041174. DOI: 10.1136/bjo.71.5.387. View

20.

Van Buren C . Cyclosporine: progress, problems, and perspectives. Surg Clin North Am. 1986; 66(3):435-49. DOI: 10.1016/s0039-6109(16)43931-9. View